 |
|
|
| |
Sofosbuvir in Combination With PegIFN and
Ribavirin for 12 Weeks Provides High SVR Rates
in HCV-Infected Genotype 2 or 3 Treatment-
Experienced Patients with and without
Compensated Cirrhosis: Results from the LONESTAR-2 Study
|
| |
| |
Reported by Jules Levin
AASLD 2013 Nov 1-4, Washington, DC
Eric Lawitz1,2, Fred Poordad1,2, Diana M. Brainard3, Robert H. Hyland3, Di An3,
William T. Symonds3, John G. McHutchison3, Fernando E. Membreno1,2
1Texas Liver Institute, San Antonio, TX; 2University of Texas Health Science Center, San Antonio, TX; 3Gilead Sciences, Inc, Foster City, CA
|
| |
|
|
|
|
|
